Market Research Reports Ankylosing Spondylitis Patient Digital Landscape | Page 2

In terms of the geographic analysis, North America dominates the global market for Ankylosing
Spondylitis. Additionally, technological advancements are driving Ankylosing Spondylitis in North
America. APAC, followed by Europe, is expected to experience high growth rate in the Ankylosing
Spondylitis Market over the next few years. China and India are expected to be the fastest-growing
Ankylosing Spondylitis Markets in the APAC region.
Top Leading Key Players in Global Ankylosing Spondylitis Market: AbbVie Inc., Janssen
Pharmaceuticals Inc., Pfizer Inc., Sandoz International GmbH, Amgen Inc., Protalix BioTherapeutics,
Inc., Reliance Life Sciences Pvt. Ltd., Momenta Pharmaceuticals Inc., Celgene Corporation,
Regeneron Pharmaceuticals, and Merck & Co. Inc and others. New product launches and continuous
technological innovations are the key strategies adopted by the major players.
Current Business News:
1 AbbVie (June 04, 2019) – AbbVie Presents Data from Venetoclax Chemotherapy-Free Combination
Regimen for Patients with Previously Untreated Chronic Lymphocytic Leukemia – AbbVie (NYSE:
ABBV), a research-based global biopharmaceutical company, today presented data from the CLL14
trial, the first randomized clinical trial to examine stopping an oral-based, chemotherapy-free
combination after 12 months in previously untreated patients with CLL and coexisting medical
conditions. The results demonstrate that venetoclax plus obinutuzumab prolonged progression-free
survival (PFS) and achieved higher rates of complete response and minimal residual disease (MRD)-
negativity compared to a commonly used standard of care obinutuzumab plus chlorambucil.1
"Conducting CLL14 was another collaborative and bold attempt to continue pushing the boundaries
of treatment in CLL," said Mohamed Zaki, M.D., Ph.D., vice president, global head of hematology
development, AbbVie. "The combination of venetoclax plus obinutuzumab significantly prolonged
progression-free survival and patients maintained that benefit after stopping treatment. After the
recent approval in the U.S., we look forward to continue working with health authorities worldwide
as we aim to bring venetoclax plus obinutuzumab to patients with previously untreated CLL."
2 Pfizer (April 26, 2019) – Pfizer Receives Positive Chmp Opinion for Talzenna (Talazoparib) for
Patients with Inherited (Germline) Brca-mutated Locally Advanced or Metastatic Breast Cancer –
Pfizer Inc., today announced that the Committee for Medicinal Products for Human Use (CHMP) of
the European Medicines Agency (EMA) adopted a positive opinion recommending TALZENNA
(talazoparib), an oral poly (ADP-ribose) polymerase (PARP) inhibitor, be granted marketing
authorization in the European Union (EU). The indication the CHMP adopted is for TALZENNA as
monotherapy for the treatment of adult patients with germline breast cancer susceptibility gene
(gBRCA)1/2-mutations, who have human epidermal growth factor receptor 2-negative (HER2-)
locally advanced (LA) or metastatic breast cancer (MBC). Patients should have been previously
treated with an anthracycline and/or a taxane in the (neo) adjuvant, locally advanced or metastatic
setting unless patients were not suitable for these treatments. Patients with hormone receptor-
positive (HR+) breast cancer should have been treated with a prior endocrine-based therapy, or be
considered unsuitable for endocrine-based therapy.
“There is a pressing need for new, effective medicines that are specifically developed for patients
with an inherited BRCA mutation who are often diagnosed at a younger age and have limited options
for the treatment of advanced-stage disease,” said Chris Boshoff, M.D., Ph.D., Chief Development